Compare SGHT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHT | STRO |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | 131 |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.0M | 338.9M |
| IPO Year | 2021 | N/A |
| Metric | SGHT | STRO |
|---|---|---|
| Price | $5.33 | $38.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $9.08 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 325.3K | 248.1K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,363,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $10.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.11 | $0.67 |
| 52 Week High | $9.24 | $41.88 |
| Indicator | SGHT | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 69.62 | 66.08 |
| Support Level | $3.29 | $0.78 |
| Resistance Level | $5.66 | N/A |
| Average True Range (ATR) | 0.38 | 3.05 |
| MACD | 0.14 | 0.12 |
| Stochastic Oscillator | 80.93 | 66.21 |
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.